ABOS News and Press, Acumen Pharmaceuticals Inc. From 09/06/23

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, a...

2023-08-11 09:52:01 ET Acumen Pharmaceuticals, Inc. (ABOS) Q2 2023 Earnings Conference Call August 08, 2023 08:00 AM ET Company Participants Alex Braun - Head-Investor Relations Dan O'Connell - Chief Executive Officer Eric Siemers - Chief Medical Officer Matt...

2023-08-08 07:43:40 ET Acumen Pharmaceuticals press release ( NASDAQ: ABOS ): Q2 GAAP EPS of -$0.28 beats by $0.07 . As of June 30, 2023, cash, cash equivalents and marketable securities totaled $172.2 million, compared to cash, cash equivalents and marketable securiti...

Positive INTERCEPT-AD Phase 1 trial results announced in July 2023 demonstrate ACU193’s potential as a differentiated antibody for the treatment of early Alzheimer’s disease Cash, cash equivalents and marketable securities of $172.2 million as of June 30, 2023, bolstered by ...

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligo...

2023-07-19 06:45:12 ET Clinical-stage biopharmaceutical company, Acumen Pharmaceuticals ( NASDAQ: ABOS ) prices an upsized underwritten public offering of ~16.77M shares at a price to the public of $7.75 per share. Gross proceeds are expected to be ~$130M. The offering...

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 18, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of A...

2023-07-18 11:32:07 ET Shares of Acumen Pharmaceuticals (NASDAQ: ABOS) were down more than 16% at 11 a.m. on Tuesday after the company announced a public stock offering. The company's shares are still up more than 50% so far this year. The clinical-stage biotech company focu...

2023-07-18 08:34:40 ET Summary Positive topline results released from phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early AD. The global market for Alzheimer's disease treatments is expected to rise past $13 billion by 2030. There was statist...

2023-07-17 17:27:38 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ) has proposed an underwritten public offering of its common stock to raise $100 million, the company said Monday. All of the shares to be sold in the offering are to be sold by the company. The underwr...